4-[(1,1-Dimethylethyl)thio]-2,5-dimethoxybenzeneethanamine | 207740-28-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(1,1-Dimethylethyl)thio]-2,5-dimethoxybenzeneethanamine
• 英文别名: 2-(4-tert-butylsulfanyl-2,5-dimethoxyphenyl)ethanamine
• CAS: 207740-28-1
• 化学式: C₁₄H₂₃NO₂S
• 分子量: 269.4
• InChiKey: PSVDMTZXLJTPNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  69.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS
  申请人：JENKINS Thomas E.

  公开号：US20120232066A1

  公开（公告）日：2012-09-13

  The present disclosure provides a composition comprising a GABA A agonist and a GI enzyme inhibitor. The present disclosure also provides a composition comprising (a) a GI enzyme inhibitor and (b) a first drug that interacts with a second drug to produce an adverse effect when the second drug is co-ingested as a GI enzyme-cleavable prodrug with the first drug. Such an interaction can be additive or synergistic.

  本公开提供一种包含GABAA激动剂和GI酶抑制剂的组合物。本公开还提供一种包含（a）GI酶抑制剂和（b）第一药物的组合物，当第二药物以GI酶可切割的前药形式与第一药物共同摄入时，第一药物与第二药物相互作用产生不良效应。这种相互作用可以是加成的或协同的。
• Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
  申请人：Jenkins Thomas E.

  公开号：US20130059914A1

  公开（公告）日：2013-03-07

  Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

  提供了药物组合物及其使用方法，其中药物组合物包括一种苯丙胺前药，该前药提供酶控释放苯丙胺或苯丙胺类似物。该组合物还可以包括一种酶抑制剂，与介导苯丙胺前药中苯丙胺或苯丙胺类似物的酶相互作用，以减弱苯丙胺前药的酶解。
• [EN] PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS<br/>[FR] PHÉNALKYLAMINES ET PROCÉDÉS DE TRAITEMENT DE TROUBLES DE L'HUMEUR
  申请人：GILGAMESH PHARMACEUTICALS INC

  公开号：WO2022006186A1

  公开（公告）日：2022-01-06

  Phenalkylamines and methods of treating mood disorders with phenalkylamines. Also provided are pharmaceutical compositions that include phenalkylamines.

  Phenalkylamines和使用Phenalkylamines治疗情绪障碍的方法。还提供了包含Phenalkylamines的制药组合物。
• Preparation of desiccated liposomes for use in compressible delivery systems
  申请人：SMARTEK INTERNATIONAL LLC

  公开号：US10195146B1

  公开（公告）日：2019-02-05

  The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

  本文件描述了一种用于经粘膜给药至少一种化合物的可压缩给药配方，其中包括微粉基质；以及一种干燥脂质体配方，其中包括至少一种含有至少一种化合物的脂质体、制作工艺以及用该配方制作剂型的工艺。
• Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
  申请人：Signature Therapeutics, Inc.

  公开号：US11179355B2

  公开（公告）日：2021-11-23

  Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

  本发明提供了药物组合物及其使用方法，其中药物组合物包含一种苯丙胺原药，该原药可酶控释放苯丙胺或苯丙胺类似物。该组合物还可以包含一种酶抑制剂，它与介导苯丙胺原药酶控释放苯丙胺或苯丙胺类似物的酶相互作用，从而减弱苯丙胺原药的酶裂解。